Top women in biotech 2014

Jennifer Levin FierceBiotech News

UPDATED: Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up

John Carroll Novartis is prepping new studies that will test how well three of its oncology drugs–the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia–do ...

Forest, Otsuka and J&J spend the most on fees and food for doctors

Carly Helfand The Sunshine Act data's been out in the open for a couple of days now (well–most of it), and despite the database's clunkiness, the number crunching is well ...

Actavis snaps up Durata, newly approved antibiotic in $675M buyout

John Carroll Buyout-hungry Actavis–which is alternatively spotlighted as both a buyer and a possible buyout target–has snapped up Chicago-based Durata Therapeutics and its ...

Peg cancer drug prices to effectiveness, ’60 Minutes’ interviewee suggests

Tracy Staton On "60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking–and politicians, too. FiercePharma ...

Sunesis shares crushed in a rout after leukemia PhIII ends in defeat

John Carroll Shares of South San Francisco-based Sunesis were crushed this morning after the biotech put out word that its drug vosaroxin had flunked a Phase III test for acute myeloid ...

Endo accused of $112M payoff in Opana pay-for-delay suit

Carly Helfand Endo Health Solutions tried hard to ward off generic competitors for its big-selling pain med Opana ER. For instance, it petitioned the FDA to block competitors on safety ...

Alcobra says its ADHD drug works–as long as you don’t compare it to placebo

Damian Garde Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo–but only after the ...

Is Teva knocking on Mylan’s door? With inversion deal at risk, maybe

Carly Helfand Teva and Mylan merge? Rumors are certainly swirling–and not for the first time, either. But while a potential deal might make financial sense, at least one analyst ...

Biotech backer Forbion raises $120M toward a new VC fund

Damian Garde The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $ 120 million with plans to stake a new generation of biotechs. FierceBiotech ...

AstraZeneca crows about Brilinta edge in new ACS treatment guidelines

Tracy Staton Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really ...

Struggling Teva slashing R&D, chops 14 programs as it retreats on two fronts

John Carroll FierceBiotech News
Page 4 of 6« First...23456
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS